ALVR -65%/PM on phase-3 futility—program termination: https://www.globenewswire.com/news-release/2023/12/22/2800535/0/en/AlloVir-Provides-Updates-on-Phase-3-Clinical-Development-Program-for-Posoleucel-an-Allogeneic-Virus-Specific-T-Cell-Therapy.html The stock is down 95% from its 2020 IPO (#msg-157261592).